Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield - SC formulary Prior Auth |…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South CarolinaPolicy N/A

    South Carolina PDP Basic - Formulary step and trial requirements

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - South Carolina policy alerts

    Know when Blue Cross Blue Shield - South Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document lists products on the South Carolina PDP Basic formulary and specific prior-authorization or step-therapy trial requirements that govern coverage and continuation of therapy for members and their providers.

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicySouth Carolina PDP Basic - Formulary step and trial requirements
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMar 1, 2026
    Last ReviewFeb 2, 2026
    Next Review DateN/A
    Key ActionFor new starts, document and provide prior trial(s) as required (for example: trial of topical fluorouracil or imiquimod for Diclofenac Sodium GEL 3%).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ~14drugs or drug groups listed
    26220

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    formulary identifier
    v10formulary version
    03/01/2026effective date
    02/02/2026last update

    Coverage Criteria by Product

    Diclofenac Sodium GEL 3% - Actinic keratosis

    Covered when ALL of the following are met:

    ALL of the following

    • 1: Trial of either topical fluorouracil or topical imiquimod

      Formulary ID 26220, Version 10, effective 03/01/2026

    Antidepressant-related products (e.g., Exxua, Auvelity, Emsam, Fetzima and packs)

    Covered when ALL of the following are met:

    ALL of the following

    • 1: Trial of two generics among: bupropion, mirtazapine, citalopram (tablet or solution), desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine hydrochloride

      Approve for continuation of prior therapy; Formulary ID 26220, Version 10, effective 03/01/2026

    Fanapt and related titration packs / Lybalvi / Secuado

    Covered when ALL of the following are met:

    ALL of the following

    • 1: Trial of two oral generic formulary atypical antipsychotic agents among: asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone

      Approve for continuation of prior therapy; Formulary ID 26220, Version 10, effective 03/01/2026

    Invega Hafyera

    Covered when ALL of the following are met:

    ALL of the following

    • 1: Trial of one of: Invega Sustenna or Invega Trinza

      Step applies to new starts only; approve for continuation of prior therapy; Formulary ID 26220, Version 10, effective 03/01/2026

    Relistor

    Covered when ALL of the following are met:

    ALL of the following

    • 1: Trial of lubiprostone, Constulose, Enulose, Generlac, or lactulose

      Formulary ID 26220

    Zonisade

    Covered when ALL of the following are met:

    ALL of the following

    • 1: Trial of generic zonisamide capsule

      Step applies to new starts only; approve for continuation of prior therapy; Formulary ID 26220, Version 10, effective 03/01/2026

    Initial (New Start) Therapy Requirements

    Initial therapy requirements

    Initial (new start) therapy requirements — step or prior trials required as specified per product.

    ALL of the following

    • Diclofenac_init: Trial of either topical fluorouracil or topical imiquimod required for Diclofenac Sodium GEL 3% new starts

      Chunk 2

    • Antidepressant_init: Trial of two generics from listed antidepressant group required for specified antidepressant/adjunct products; continuation allowed

      Chunk 4

    • Fanapt_init: Trial of two generic atypical antipsychotics required for Fanapt products new starts

      Chunk 6

    Continuation of Prior Therapy

    Continuation approvals

    Continuation of prior therapy is approved for listed products when members are already receiving therapy.

    ANY of the following

    • continuation: Approve for continuation of prior therapy when member is already on the medication

      Applies across multiple listed products

    Continuation of prior therapy — summary
    DefinitionContinuation of prior therapy: approval to continue coverage when a member is already receiving the medication.
    ApplicabilityApplies across listed atypical antipsychotic products including Fanapt, Fanapt titration packs, Lybalvi, and Secuado.
    Action for providers

    Step Therapy Requirements (New Starts)

    ProductStep requirement (new starts)
    Fanapt (including Fanapt titration packs)Trial of two oral generic formulary atypical antipsychotic agents among: asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone
    ProductStep requirement (new starts)
    Antidepressant-related products (e.g., Exxua Titration Pack, Fetzima, Fetzima Titration Pack)Trial of two generics among: bupropion, mirtazapine, citalopram (tablet or solution), desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine hydrochloride
    ProductStep requirement (new starts)
    Invega HafyeraTrial of one of: Invega Sustenna or Invega Trinza (step applies to new starts only)
    ZonisadeTrial of generic zonisamide capsule (step applies to new starts only)

    Provider Action & Documentation Requirements

    Prior Authorization

    Diclofenac Sodium GEL 3% prior auth

    Prior authorization for Diclofenac Sodium GEL 3% requires documentation of a trial and lack of response or intolerance to either topical fluorouracil or topical imiquimod. Failure to document the required prior trial may result in denial of the prior authorization request.

    • Affected product: Diclofenac Sodium GEL 3%
    Prior Authorization

    Antidepressant products prior auth

    Prior authorization for select antidepressant products (including Exxua Titration Pack, Fetzima, and Fetzima Titration Pack) requires trial of two generic agents from the following group: bupropion, mirtazapine, citalopram (tablet or solution), desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine hydrochloride. Lack of documented trials for new starts may lead to non-approval. Continuation of prior therapy is approved when prior use is documented.

    • Affected products: Exxua Titration Pack; Fetzima; Fetzima Titration Pack

    Background

    This policy lists formulary-specific prior authorization and step-therapy requirements that apply to the South Carolina PDP Basic formulary (Formulary ID 26220, Version 10, effective 03/01/2026, last updated 02/02/2026). The requirements are intended to ensure use of formulary or generic alternatives where appropriate before coverage of select brand or specialty products, while allowing continuation of prior therapy for members already receiving the medication.

    The document identifies specific initial (new start) therapy rules—for example, required trials of topical therapies for actinic keratosis, trials of listed generic antidepressants or atypical antipsychotics, and step requirements for certain long‑acting or specialty agents—and lists the products subject to those rules. It also specifies the documentation providers must submit to support prior authorization requests and notes the denial risk when required trials are not documented.

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicySouth Carolina PDP Basic - Formulary step and trial requirements
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMar 1, 2026
    Last ReviewFeb 2, 2026
    Next Review DateN/A
    Key ActionFor new starts, document and provide prior trial(s) as required (for example: trial of topical fluorouracil or imiquimod for Diclofenac Sodium GEL 3%).
    SourceLink
    On This Page
    Coverage Criteria by ProductInitial (New Start) Therapy RequirementsContinuation of Prior TherapyStep Therapy Requirements (New Starts)Provider Action & Documentation RequirementsBackground
  1. Invega_init: Trial of Invega Sustenna or Invega Trinza required for Invega Hafyera new starts

    Chunk 8

  2. Relistor_init: Trial of specified laxatives (lubiprostone, Constulose, Enulose, Generlac, or lactulose) required for Relistor

    Chunk 10

  3. Zonisade_init: Trial of generic zonisamide capsule required for Zonisade new starts

    Chunk 12

  4. For continuation requests, document prior use/supply of the medication to support approval.
    Most actionableApprove for continuation of prior therapy when member is already on the medication (no new-step trials required for continuation).
    ReferenceFormulary ID 26220; Version 10; Effective 03/01/2026; Last Updated 02/02/2026.
    Prior Authorization

    Fanapt prior auth

    For Fanapt products (including Fanapt Titration Pack C, Lybalvi, Secuado), prior authorization for new starts requires documentation of trial and failure or intolerance of two oral generic formulary atypical antipsychotics from the list: asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone. Continuation of prior therapy is approved when prior use is documented. Absence of these documented trials for new starts may result in denial.

    • Required trial agents: asenapine; aripiprazole; olanzapine; paliperidone; quetiapine; risperidone; ziprasidone
    • Affected products: Fanapt Titration Pack C; Lybalvi; Secuado
    Step Therapy

    Invega Hafyera prior auth

    Invega Hafyera prior authorization for new starts requires documentation of trial and inadequate response or intolerance to either Invega Sustenna or Invega Trinza. Step therapy applies to new starts only. Continuation of prior therapy is approved when prior use is documented; provide supply records or prior administration history to support continuation. Lack of a required prior trial may trigger denial for new starts.

    • Step therapy: new starts must try Invega Sustenna or Invega Trinza first
    • Documentation: supply records or prior administration history for continuation requests
    Prior Authorization

    Relistor prior auth

    Prior authorization for Relistor requires documentation of a trial and inadequate response to one of the following laxatives: lubiprostone, Constulose, Enulose, Generlac, or lactulose. Absence of a documented trial of these agents may result in denial.

    • Affected product: Relistor
    • Required prior agents: lubiprostone; Constulose; Enulose; Generlac; lactulose
    Prior Authorization

    Zonisade prior auth

    Zonisade prior authorization for new starts requires documentation of trial and failure or intolerance of a generic zonisamide capsule. Step therapy applies to new starts only. Continuation of prior therapy is approved when prior use is documented. Lack of the required trial for new starts may result in non-approval.

    • Required prior agent: generic zonisamide capsule
    • Step therapy: applies to new starts only
    Denial Risk

    Provider documentation and denial risk

    Document trials, failures, or intolerances of the required prior agents when submitting prior authorization requests. Failure to provide the requested documentation (e.g., trials of topical fluorouracil or imiquimod for Diclofenac Sodium GEL 3%, two generic antidepressants for certain antidepressant products, two generic atypical antipsychotics for Fanapt products, Invega Sustenna or Trinza for Invega Hafyera, specified laxatives for Relistor, or generic zonisamide for Zonisade) may lead to denial or non-approval of the request.

    • Provide dates, duration, and reason for discontinuation (failure or intolerance) where applicable
    • Include supply records or prior administration history for continuation requests